Dr. Richard Marshall, CBE, MD, PhD

Chief Executive Officer

Dr. Richard Marshall is a physician scientist and a highly experienced executive with a 20-year track record of outstanding leadership in Pharmaceutical R&D. He is driven by a passion for developing new medicines to treat diseases of high unmet need and is excited to lead Juvenescence on its mission to improve the healthspan of people globally.

Most recently, Richard was Senior Vice President and Global Head of Respiratory & Immunology Development at AstraZeneca, overseeing the development and approval of five new medicines. This included the SARS CoV-2 vaccine, Vaxzevria, and combination antibody, Evusheld. In 2021 he was recognized in the Queen’s Honours List with a CBE for his contribution to UK science and the Covid response.

Before joining AstraZeneca, Richard held increasingly senior roles at GlaxoSmithKline and was Vice President of Fibrosis R&D. He
trained at UCL and has held visiting professor and honorary consultant roles in thoracic medicine at Newcastle University and the Royal Brompton Hospital. Throughout his career, Richard has co-authored >60 original publications in journals including The Lancet and The New England Journal of Medicine.

In the Media with Richard Marshall

[Interview] - Longevity Technology Interviews Richard Marshall on Juvenescence's Mission & His Role as CEO.

Our CEO, Richard Marshall talks with Longevity Technology about Juvenescence’s mission, pipeline and where he sees future potential.